ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

12,207Medicare Part D Prescriptions Filled, Including Refills

Rank: 128 out of 783

$662K Total Retail Price of All Prescriptions

Rank: 156 out of 783

393 Patients Receiving at Least One Drug in Part D
86%Patients 65 Years and Older
32% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Indiana
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

17% of this provider’s 393 patients filled at least one prescription for a schedule three drug, compared to an average of 16%.

Risky Drugs to Seniors

2% of this provider’s 10,978 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

29% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$54 was the average price of a prescription from this provider, compared to $61 among peers.

Prescriptions per Patient

31 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Indiana
SIMVASTATIN 627 593 1 3
LEVOTHYROXINE SODIUM 487 441 2 1
OMEPRAZOLE 441 384 3 6
POTASSIUM CHLORIDE 395 349 4 16
LISINOPRIL 387 356 5 4
FUROSEMIDE 377 330 6 7
HYDROCODONE-ACETAMINOPHEN 320 241 S3 7 2
AMLODIPINE BESYLATE 288 267 8 5
METOPROLOL SUCCINATE 251 240 9 13
WARFARIN SODIUM 208 189 10 10
CITALOPRAM HBR 205 172 11 19
ATENOLOL 178 178 12 17
HYDROCHLOROTHIAZIDE 172 160 13 12
NAMENDA 170 170 14 32
LOSARTAN POTASSIUM 168 138 15 18
DIOVAN 164 159 16 49
ALENDRONATE SODIUM 160 155 17 25
PRAVASTATIN SODIUM 155 140 18 14
METOPROLOL TARTRATE 149 142 19 9
METFORMIN HCL 149 113 19 8
CRESTOR 136 129 21 27
BYSTOLIC 119 110 22 99
MELOXICAM 115 109 23 37
CLOPIDOGREL 112 102 24 29
ESCITALOPRAM OXALATE 105 100 25 54
GLIMEPIRIDE 103 97 26 34
TRAMADOL HCL 96 85 27 20
ISOSORBIDE MONONITRATE ER 90 85 28 40
SPIRONOLACTONE 89 74 29 57
GABAPENTIN 89 84 29 15
SYNTHROID 84 73 31 47
ZOLPIDEM TARTRATE 83 75 32 23
KLOR-CON 10 80 80 33 102
KLOR-CON M20 79 79 34 48
LOVASTATIN 73 73 35 58
SERTRALINE HCL 73 73 35 22
CARVEDILOL 72 65 37 21
ACTOS 71 49 38 149
TAMSULOSIN HCL 69 69 39 26
MECLIZINE HCL 68 67 40 146
PLAVIX 67 62 41 51
ALLOPURINOL 66 62 42 31
HUMALOG 66 65 42 101
ATORVASTATIN CALCIUM 64 59 44 11
BENICAR 63 53 45 182
LISINOPRIL-HYDROCHLOROTHIAZIDE 63 31 45 33
FLUTICASONE PROPIONATE 62 37 47 46
DIGOXIN 61 59 48 61
SPIRIVA 61 52 48 59
ZETIA 59 59 50 80
PREDNISONE 57 55 51 36
ADVAIR DISKUS 56 39 52 50
MICARDIS 55 42 53 326
MIRTAZAPINE 53 53 54 52
DILTIAZEM ER 52 52 55 153
LANTUS 51 36 56 38
NEXIUM 50 38 57 28
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on April 28, 2009.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.